このエントリーをはてなブックマークに追加
ID 34996
file
creator
Ishihara, Aiko
Miyachi, Takafumi
Nakamura, Takeshi
Ohtsuki, Toshiho
Yamawaki, Takemori
subject
Parkinson's disease
3-OMD
Entacapone
Levodopa AUC
NDC
Medical sciences
abstract
The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMTindex was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone.
journal title
Hiroshima Journal of Medical Sciences
volume
Volume 60
issue
Issue 3
start page
57
end page
62
date of issued
2011-09
publisher
Hiroshima University Medical Press
issn
0018-2052
ncid
language
eng
nii type
Departmental Bulletin Paper
HU type
Departmental Bulletin Papers
DCMI type
text
format
application/pdf
text version
publisher
rights
(c) Hiroshima University Medical Press.
department
Graduate School of Biomedical Science
University Medical Hospital
他の一覧